A qualitative review of recent economic evaluations of escitalopram

Journal of Pharmacy Technology

Volumn 23, Issue 1, 2007, Pages 35-40

  Sadri, Hamid ^a,e   Mittmann, Nicole ^b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c HOPE Research Centre   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM;

CANADA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; EMBASE; EUROPE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; PUBLICATION; QUALITATIVE RESEARCH; REVIEW;

EID: 33847131977     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250702300107     Document Type: Review

References (29)

1. Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 2000;1:3-10.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
3. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003;12:22-33.
4. Isaac M. Where are we going with SSRIs? Eur Neuropsychopharmacol 1999;9(suppl 3):S101-6.
5. Waugh J, Goa K. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17:343-62.
6. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15:193-8.
7. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrum 2002;7:40-4.
8. Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psych Clin Pract 2003;7:259-68.
9. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int J Psychopharmacol 2004;19:305-10.
10. Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 2004;30:158-66.
11. Montgomery SA, Huusom AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64. DOI 10.1159/000078225
12. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6.
13. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003;289:3135-44.
14. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183:514-9.
15. Greenberg PE, Stigline LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
16. Henriksson F, Jonsson B. Halsoekonomiska aspekter pa depressionssjukdomen. In: Asberg M, Bengtsson F, Hagberg B, eds. Behandling av depressionssjukdomar. En systematisk litteratur-oversikt. SBU Rapport: 2004:403-36.
17. Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981-2000. Ann Pharmacother 2002;36:1375-9. DOI 10.1345/aph.1A331
18. Croom KF, Plosker GL. Escitalopram. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 2003;21:1185-209.
19. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004;20:869-78.
20. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004;38:954-60. Epub 27 Apr 2004. DOI 10.1345/aph.1E010
21. Hemels MEH, Rocchi A, Kennedy S, Rousseau M. Economic evaluation of first-line treatment for depression in primary care: a Canadian probabilistic cost-effectiveness model. Can J Clin Pharmacol 2005;12:e45.
22. Hemels MEH, Karamustafalyoglu O, Ozmen E, Dislad S, Mene S. Cost-effectiveness analysis of escitalopram in the treatment of major depressive disorder in Turkey. Value in Health 2005;8:392. DOI 10.1111/j.1524-4733.2005. 08304.x
23. Hemels MEH, Sorensen J, Stage KB, Damsbo N, Lelay A. Probabilistic cost-effectiveness model of escitalopram compared with citalopram and venlafaxine in the first-line treatment of major depressive disorder in Denmark. A Seminar in Denmark. 2005.
24. Löthgren M, Hemels MEH, Francois C, Jonsson B. A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Primary Care Psychiat 2004;9:153-61.
25. Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21:631-42.
26. Wade AG, Toumi I, Hemels MEH. A pharmacoeconomic evaluation of escitalopram versus citalopram in treatment of severe depression in the United Kingdom. Clin Ther 2005;27:486-96.
27. Demyttenaere K, Hemels MEH, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-24.
28. Kulp W, von der Schulenburg JM, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 2005;6:317-21. DOI 10.1007/s10198-005-0306-1
29. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-67.